icovamenib   Click here for help

GtoPdb Ligand ID: 13456

Synonyms: BMF-219 | BMF219 | Compound 10 [US20200223853A1]
Compound class: Synthetic organic
Comment: Icovamenib (BMF-219) is an orally bioavailable, irriversible (covalent) menin inhibitor (structure from [2]). In mixed lineage leukaemia gene (MLL)-rearranged leukaemias menin drives leukaemic transformation through a direct interaction with the MLL protein (a histone methyltransferase encoded by the KMT2A gene). Inhibitors of the MLL-menin interaction are being developed as a novel therapeutic class to block leukaemogenesis and induce apoptosis of leukaemic blasts as an approach for the treament of aggressive haematopoietic malignancies [2]. Menin also interacts with and regulates activity of the MYC transcription factor/oncoprotein, so menin inhibitors may also be of value in MYC-driven cancers [3].
BMF-219 is one of the menin inhibitor compounds claimed in patent US20200223853A1 (as Compound 10) [1].

icovamenib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 123.02
Molecular weight 566.65
XLogP -0.23
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C=CC(=O)N[C@@H]1CCCN(CC2=CC=NC(=C2)C(=O)NC3=CC=C(C=C3)C4=CC5=C(N=CN=C5N4)N6CCOCC6)C1
Isomeric SMILES C=CC(=O)N[C@@H]1CCCN(CC2=CC(=NC=C2)C(=O)NC3=CC=C(C=C3)C4=CC5=C(N4)N=CN=C5N6CCOCC6)C1
InChI InChI=1S/C31H34N8O3/c1-2-28(40)35-24-4-3-11-38(19-24)18-21-9-10-32-27(16-21)31(41)36-23-7-5-22(6-8-23)26-17-25-29(37-26)33-20-34-30(25)39-12-14-42-15-13-39/h2,5-10,16-17,20,24H,1,3-4,11-15,18-19H2,(H,35,40)(H,36,41)(H,33,34,37)/t24-/m1/s1
InChI Key CPRLHPSXWZTPMC-XMMPIXPASA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Icovamenib (BMF-219) is in clinical evaluation to determine safety and efficacy for the treament of select haematopoietic malignancies and advanced solid tumours. The FDA placed a full clinical hold on BMF-219 studies in diabetes in June 2024, due to concerns regarding observed possible drug-induced hepatotoxicity (liver enzyme elevations) in one of the studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05631574 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1 Interventional Biomea Fusion Inc.
NCT05153330 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL Phase 1 Interventional Biomea Fusion Inc.